COVID-19: Pathophysiology, Clinical Management, Therapeutic Evidence & Ongoing Trials – Grand Rounds, May 13

May 13, 2020 @ 9am-10am

In this upcoming UBC DEM Grand Rounds, membersĀ Dr. Adam Thomas and Dr. David Sweet will discuss the latest therapeutic evidence, pathophysiology, and clinical management of COVID-19.

Both Adam and David are members of the BC COVID-19 Therapeutics Committee (CTC) and recently published new Clinical Practice Guidance for Antimicrobial and Immunomodulatory Therapy in Adult Patients with COVID-19.

Learning Objectives for Rounds

1) Discuss the unique pathophysiology of COVID-19 including alterations to traditional ARDS definitions with L and H phenotype respiratory failure, Cytokine storm and prothrombotic states.

2) Understand how this unique pathophysiology of COVID-19 alters clinical management.

3) Review associated COVID-19 specific sequela of organ dysfunction outside of respiratory failure

4) Review up to date evidence on various COVID-19 antiviral and immunomodulating therapy and the RCTs currently planned or underway.

Speakers
EM Network Members Dr. Adam Thomas & Dr. David Sweet

Join Online
https://ubc.zoom.us/j/6734537810

Please keep your microphone muted.

SHARE